Write your message
Volume 7, Issue 6 (November - December 2022)                   J Obstet Gynecol Cancer Res 2022, 7(6): 507-512 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akbari H, Forouzandeh H, Reza Mirshekari T, Kashfi S A, Ghavamizadeh M. Prevalence and Correlates of the Estrogen and Progesterone Receptors (ER/PR), Human Epidermal Growth Factor Receptor-2 (HER-2) and P53 in Breast Cancer: a Cross-Sectional Study. J Obstet Gynecol Cancer Res. 2022; 7 (6) :507-512
URL: http://jogcr.com/article-1-563-en.html
1- Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
2- Department of Pathology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
3- Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran , mehdighavamiz@gmail.com
Abstract:   (153 Views)

Background & Objective: Breast cancer has a pivotal role in many deaths caused by malignancies. Epidermal growth factor receptor-2 (EGFR-2 or HER-2) and estrogen receptor (ER) have immense predictive values as prognostic factors. Breast cancers that have steroid receptors and respond to hormone therapy show a better prognosis than cancers without steroid receptors.
Materials & Methods: A retrospective cross-sectional study was performed on 500 pathology blocks of women with breast cancer sent to the pathology department of Amir-al-Momenin medical and educational center, Gerash, Iran, from 2016 to 2019. Data were analyzed by SPSS software (Version-16) via ANOVA test followed by Chi-square and t-tests. P-value <0.05 was considered as significant.
Results: The utmost type of malignancy was invasive ductal carcinoma (IDC) at 35.03%. Among ER-positive patients 59.67% were HER-2-positive. Nonetheless, among the PR-positive patients 54.74% were HER-2-positive. ER-positive patients were correlated with p53 receptor, distant metastasis and HER-2 significantly (P<0.01). However, PR-positive patients just correlated with p53 receptor significantly (P<0.01).
Conclusion: Investigated samples were more ER-negative and less PR-positive compared to similar studies. Meanwhile, ER-positive patients were HER-2-positive. Regarding the correlation with prognosis of breast cancer, especially in HER-2-positive patients, there is a need to perform profound screening programs for HER-2 in breast cancer patients, especially with histopathological characteristics of invasive ductal carcinoma.

     
Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2021/12/4 | Accepted: 2022/02/5 | Published: 2022/09/9

References
1. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1-2):373-86. [DOI:10.1016/j.cell.2017.11.010] [PMID]
2. Zahmatkesh B, Keramat A, Alavi N, Khosravi A, Kousha A, Motlagh AG, et al. Breast cancer trend in Iran from 2000 to 2009 and prediction till 2020 using a trend analysis method. Asian Pac J Cancer Prev. 2016;17(3):1493-8. [DOI:10.7314/APJCP.2016.17.3.1493] [PMID]
3. Keyhanian S, Jannat alipoor Z, Lohrasbi E, Fotoukian Z, Saravi M. Evaluation of Biologic Markers Frequency and Their Correlation with Some Determinant Prognostic Factors in Women with Breast Cancer Referred to Oncology Clinic of Imam Sajjad Hospital of Ramsar during 2002-2012. J Ilam Univ Med Scienc. 2015;22(7):115-28.
4. Khader YS, Sharkas GF, Arkoub KH, Alfaqih MA, Nimri OF, Khader AM. The epidemiology and trend of cancer in Jordan, 2000-2013. J Cancer Epidemiol. 2018;2018: Article ID 2937067. [DOI:10.1155/2018/2937067] [PMID] [PMCID]
5. Moghni M, Mokhtariyan K. Correlations of estrogen or progesterone receptors with grade of invasive ductal carcinomas of the breast in women referred to pathology center in Chaharmahal va Bakhtiari province Iran. J Shahrekord Univ Med Sci. 2009;11(3):40-5.
6. Shahidsales S, Hosseini S, Ahmadi-Simab S, Ghavam-Nasiri M. The importance of Prognostic factors (ER, PR, P53) in breast cancer and their relationship with stage of disease. Med j Mashhad Univ Med Scienc. 2014;57(2):457-63.
7. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52:56-73. [DOI:10.1016/j.semcancer.2017.08.010] [PMID]
8. 8 Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100-7. [DOI:10.1097/PAP.0000000000000015] [PMID]
9. Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10-20. [DOI:10.1016/j.ctrv.2018.04.016] [PMID]
10. Moulder DE, Hatoum D, Tay E, Lin Y, McGowan EM. The roles of p53 in mitochondrial dynamics and cancer metabolism: the pendulum between survival and death in breast cancer? Cancers. 2018;10(6):189. [DOI:10.3390/cancers10060189] [PMID] [PMCID]
11. Jalava P, Kuopio T, Huovinen R, Laine J, Collan Y. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res. 2005;25(3C):2535-42.
12. Sirati F, Ghahari A, Alavi N. Determine the prevalence of prognostic factor) ER, PR, P53, HER-2/neu (in Breast Cancer and investigate their relationship with each other and with the patient's age and menopausal status. AlternIran J Breast Disate Iran J Breast Dis. 2009;1(3):24-31.
13. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):1-10. [DOI:10.1186/bcr1639] [PMID] [PMCID]
14. Tehrani F, Khazaeian K, Malayeri A, Faghani R. Correlation of HER2 overexpression with histopathologic features in breast cancer: a two-year study. Tehran Univ Med J. 2010;67(11).
15. Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. J Coll Physicians Surg Pak. 2005;15(4):230-3.
16. Baisil S, Kundapur R, Chandramoha S, Nelliyanil M, Abhraham P, Shetty V, et al. Survival Pattern Depending on Hormone Receptor Status, Stages of Breast Cancer and Social-Economic Status-A Cohort Study. J Obstet Gynecol Cancer Res. 2022;7(3):221-5. [DOI:10.30699/jogcr.7.3.221]
17. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519-27. [DOI:10.1016/j.canep.2015.04.016] [PMID]
18. Xu L, Bai ZH, Xu RC, Yan H, Wang FJ, Luo RC. Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications. J South Med Univ. 2006;26(2):231-3.
19. Gohari MR, Abolghasemi J, Mohammadi M. Prognostic factors of metastases in breast cancer patients using the recurrent Andersen-Gill model. Koomesh. 2013;14(4):483-9.
20. Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, et al. Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Med Oncol. 2010;27(3):747-52. [DOI:10.1007/s12032-009-9279-8] [PMID]
21. Daoud SA, Ismail WM, Abdelhamid MS, Nabil TM. Possible prognostic role of HER2/Neu in ductal carcinoma in situ and atypical ductal proliferative lesions of the breast. Asian Pac J Cancer Prev. 2016;17(8):3733-6.
22. Kargar S, Farzane A. Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy. J Shahid Sadougi Univ Med Scien Health Therap Service Yazd. 2013;21(4).
23. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med. 2011;236(5):567-79. [DOI:10.1258/ebm.2011.011007] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.